title: BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
abstract: OBJECTIVE
  The object of this study was to test the hypothesis that BRAF is a low-risk susceptibility gene for low malignant potential (LMP) ovarian cancer. A recent study of the relationship between BRAF polymorphisms and malignant melanoma identified strong linkage disequilibrium across the BRAF gene with one of the three most common haplotypes (haplotype C) having a population attributable risk of approximately 1.6%. We therefore hypothesized that the same BRAF haplotype may confer an increased risk of serous ovarian tumors of low malignant potential.
  
  
  METHODS
  We genotyped 383 cases of LMP ovarian cancer, including 234 of serous histology, and 987 controls for seven SNPs, representative of the most common BRAF gene haplotypes, using MALDI-TOF mass spectrometry.
  
  
  RESULTS
  Haplotype information was obtained for 369 LMP ovarian cancer cases and 983 healthy controls. None of the haplotypes were found to be associated with risk of LMP ovarian cancer (OR for haplotype C 0.81, 95% CI = 0.54-1.22), or with the risk of serous LMP ovarian cancer (OR for haplotype C 0.90, 95% CI = 0.56-1.45).
  
  
  CONCLUSIONS
  We found no evidence to suggest that BRAF is a low-risk LMP ovarian cancer susceptibility gene.
authors.affiliation: Queensland Institute of Medical Research, 300 Herston Rd, Herston, QLD 4006, Australia.
authors.forename: Livia
authors.initials: L
authors.lastname: Kelemen
authors.forename: Michael
authors.initials: M
authors.lastname: James
authors.forename: Amanda
authors.initials: A
authors.lastname: Spurdle
authors.forename: Ian
authors.initials: I
authors.lastname: Campbell
authors.forename: Jenny
authors.initials: J
authors.lastname: Chang-Claude
authors.forename: David
authors.initials: D
authors.lastname: Peel
authors.forename: Hoda
authors.initials: H
authors.lastname: Anton-Culver
authors.forename: Andrew
authors.initials: A
authors.lastname: Berchuck
authors.forename: Joellen
authors.initials: J
authors.lastname: Schildkraut
authors.forename: Alice
authors.initials: A
authors.lastname: Whittemore
authors.forename: Valerie
authors.initials: V
authors.lastname: McGurie
authors.forename: Richard A
authors.initials: RA
authors.lastname: DiCioccio
authors.forename: David
authors.initials: D
authors.lastname: Duffy
authors.forename: Georgia
authors.initials: G
authors.lastname: Chenevix-Trench
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D018284:Cystadenocarcinoma, Serous / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D005260:Female; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf